** Shares of medical device maker Baxter BAX.N down 10.9% at $25 premarket
** BAX posts Q2 adj. profit of 54 cents per share, compared with analysts' estimate of 61 cents per share, according to data compiled by LSEG
** It reports Q2 sales of $2.81 billion, below estimates of $2.82 billion
** Company expects Q3 adj. profit in the range of 58 cents to 62 cents per share, below estimates of 65 cents
** Up to last close, stock down 3.8% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.